Osivax - clinical proof of concept of OVX836, a single-shot broadly protective influenza a vaccine for immediate protection against emerging pandemic strains
Active Definitive Contract Awarded Last action
- Contract number
- 75A50125C00008
- Awardee
-
Osivax UEI M4YDKJJRJYC7
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $19,485,392
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · Posted Oct 16, 2017
- Contract value 20% obligated
-
- $19,485,392.00 Current, with exercised options
- $98,593,151.00 Potential, with all options
- Completion date 43% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- France
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $19,485,392 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $98.6 million definitive contract to Osivax for clinical proof-of-concept studies of OVX836, a single-shot broadly protective influenza A vaccine designed for immediate protection against emerging pandemic strains, on July 25, 2025.
The contract employs cost-sharing pricing and carries no set-aside designation. Place of performance is France, with an ultimate completion date of July 24, 2028. The originating solicitation was a Broad Agency Announcement issued by the Biomedical Advanced Research and Development Authority (BARDA) seeking advanced research and development of medical countermeasures against pandemic influenza and other biological threats, with evaluation criteria focused on technical merit, relevance to BARDA's mission, and available funding.
Quick answers
Who was awarded contract 75A50125C00008?
75A50125C00008 was awarded to Osivax by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 25, 2025.
How much is contract 75A50125C00008 worth?
The government has obligated $19,485,392 on 75A50125C00008. Its potential value, with all options, is $98,593,151.
Was contract 75A50125C00008 competed?
The extent of competition for 75A50125C00008 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award